Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: The RESTORE extension study

Current Medical Research and Opinion

Volumn 31, Issue 11, 2015, Pages 1967-1975

  Mitchell, Paul ^a   Massin, Pascale ^b   Bressler, Susan ^c   Coon, Cheryl D ^d   Petrillo, Jennifer ^e   Ferreira, Alberto ^e   Bressler, Neil M ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b HÔPITAL LARIBOISIÈRE   (France)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Outcometrix   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Diabetic retinopathy; Macular edema; Ranibizumab; Retina

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FEMALE; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIDDLE AGED; MONOTHERAPY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; AGED; CLINICAL TRIAL; DIABETIC RETINOPATHY; MACULAR EDEMA; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE;

AGED; ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; SURVEYS AND QUESTIONNAIRES; VISUAL ACUITY;

EID: 84947488379     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1081880     Document Type: Article

References (22)

1. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116: 497-503
2. Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year incidence of visual impairment in type 1 diabetes mellitus: the Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 2010; 117: 63-70
3. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105: 998-1003
4. Hariprasad SM, Mieler WF, Grassi M, et al. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 2008; 92: 89-92
5. Okamoto F, Okamoto Y, Fukuda S, et al. Vision-related quality of life and visual function after vitrectomy for various vitreoretinal disorders. Invest Ophthalmol Vis Sci 2010; 51: 744-51
6. Gabrielian A, Hariprasad SM, Jager RD, et al. The utility of visual function questionnaire in the assessment of the impact of diabetic retinopathy on vision-related quality of life. Eye (Lond) 2010; 24: 29-35
7. Loftus JV, Sultan MB, Pleil AM. Changes in vision-And health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Invest Ophthalmol Vis Sci 2011; 52: 7498-505
8. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119: 1050-8
9. Suner IJ, Kokame GT, Yu E, et al. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 2009; 50: 3629-35
10. Hirneiss C. The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life. Clin Ophthalmol 2014; 8: 1703-9
11. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-25
12. Mitchell P, Bressler N, Tolley K, et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmology 2013; 131: 1339-47
13. Ishibashi T, Li X, Koh A, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology 2015; 122: 1402-15
14. Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013; 120: 2004-12
15. Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 2014; 121: 1045-53
16. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94: 761-74
17. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better-or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010; 117: 747-56 e744
18. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 2006; 4: 97
19. Brown DM, Nguyen QD, Marcus DM, et al. Long-Derm outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-22
20. Kenward MG, Molenberghs G. Last observation carried forward: a crystal ball? J Biopharm Stat 2009; 19: 872-88
21. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801
22. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-77 e1035